Nkarta, Inc. (NKTX): Cash & Equivalents
$39.63M
As of 2025-12-31
$24.96M
As of 2026-06-30
+1.9%
3-year compound annual growth
-16.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $39.63M | +42.2% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $27.87M | -10.2% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $31.04M | -17.2% | 2025-03-26, Balance as of period end |
| 2022-12-31 | $37.49M | -38.3% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $60.82M | -37.1% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $96.69M | +369.2% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $20.61M | n/a | 2021-03-25, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Nkarta, Inc. (NKTX) | 2025-12-31 | $39.63M | +42.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare NKTX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗